Jaclyn Mallard, PhD
Jaclyn Mallard, PhD
Director of Administration and Education
Center for Computational Biomedicine
Harvard Medical School
Dr. Jaclyn Mallard earned her Bachelor’s degree in Biochemistry and Molecular Biology from Michigan State University and later earned a PhD in Biology with a focus on Immunology from Boston College. Before beginning her graduate program, Dr. Mallard spent several years teaching and tutoring students from the elementary, high school and college levels. She moved to Boston in 2010 and worked as a Research Technician at Massachusetts General Hospital for 3 years, researching the immune response to transplantation. Dr. Mallard began her graduate training in 2013, studying the immune response to HIV infection in the brain under Professor Ken Williams at Boston College. Throughout graduate school, she continued to teach and tutor undergraduate and graduate students. She completed her PhD in 2018 then briefly worked as a postdoc in Professor Williams lab, shifting her research focus to identifying adjunctive therapies for HIV-associated disease in the central nervous system.
Toward the end of her graduate training, Dr. Mallard became interested in the strategic management of research and education. She was selected to participate in volunteer consulting teams through Tufts Medical School and MIT, where she worked on a team to develop a go-to-market strategy and a growth strategy for local startup companies. Dr. Mallard was selected to lead one of the consulting teams at MIT, where she selected a startup company from a pool of applicants, then built and managed a team to help the company build a pricing strategy for domestic and international markets. After her postdoc, she worked in professional consulting for 1 year, where she worked with multiple teams on a range of projects from mapping patient journeys, pricing analysis, competitive market analysis and strategic design of clinical trials for small and large pharmaceutical companies. From 2019-2021, Dr. Mallard worked as the Program Manager for the Chief Academic Officer at Beth Israel Deaconess Medical Center, where she managed the internal assessment, synthesis and launch of the hospitals 5 year strategic plan for research, education and innovation.
Dr. Mallard joined the Center for Computational Biomedicine in July 2021 as the Center Administrator, where she’s responsible for strategic planning and operations for CCB’s Education, Project Collaborations and Professional Development initiatives along with general administrative management of center staff.
Animal models of HIV-associated disease of the central nervous system.
Authors: Mallard J, Williams KC.
Handb Clin Neurol. 2018;152:41-53. doi: 10.1016/B978-0-444-63849-6.00004-9.
Correction to: An SIV macaque model of SIV and HAND: the need for adjunctive therapies in HIV that target activated monocytes and macrophages.
Authors: Mallard J, Williams K.
J Neurovirol. 2018 Oct;24(5):664. doi: 10.1007/s13365-018-0650-4.
An SIV macaque model of SIV and HAND: the need for adjunctive therapies in HIV that target activated monocytes and macrophages.
Authors: Mallard J, Williams K.
J Neurovirol. 2018 Apr;24(2):213-219. doi: 10.1007/s13365-018-0616-6. Epub 2018 Feb 12.
A method for obtaining simian immunodeficiency virus RNA sequences from laser capture microdissected and immune captured CD68+ and CD163+ macrophages from frozen tissue sections of bone marrow and brain.
Authors: Mallard J, Papazian E, Soulas C, Nolan DJ, Salemi M, Williams KC.
J Immunol Methods. 2017 Mar;442:59-63. doi: 10.1016/j.jim.2017.01.003. Epub 2017 Jan 14.
Non-human primate models of SIV infection and CNS neuropathology.
Authors: Williams K, Lackner A, Mallard J.
Curr Opin Virol. 2016 Aug;19:92-8. doi: 10.1016/j.coviro.2016.07.012. Epub 2016 Aug 18.
Diphtheria toxin-based recombinant murine IL-2 fusion toxin for depleting murine regulatory T cells in vivo.
Authors: Wei M, Marino J, Trowell A, Zhang H, Stromp Peraino J, Rajasekera PV, Madsen JC, Sachs DH, Huang CA, Benichou G, Wang Z.
Protein Eng Des Sel. 2014 Sep;27(9):289-95. doi: 10.1093/protein/gzu034.
Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells.
Authors: Peraino JS, Zhang H, Rajasekera PV, Wei M, Madsen JC, Sachs DH, Huang CA, Wang Z.
J Immunol Methods. 2014 Mar;405:57-66. doi: 10.1016/j.jim.2014.01.008. Epub 2014 Jan 24.
Development of a diphtheria toxin-based recombinant porcine IL-2 fusion toxin for depleting porcine CD25+ cells.
Authors: Peraino JS, Schenk M, Li G, Zhang H, Farkash EA, Sachs DH, Huang CA, Duran-Struuck R, Wang Z.
J Immunol Methods. 2013 Dec 15;398-399:33-43. doi: 10.1016/j.jim.2013.09.006. Epub 2013 Sep 18.
Molecular basis of cross-species reactivities of human versus porcine CTLA-4.
Authors: Peraino JS, Zhang H, Li G, Huang CA, Wang Z.
Hum Immunol. 2013 Jul;74(7):842-8. doi: 10.1016/j.humimm.2013.04.002. Epub 2013 Apr 18.
A truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin.
Authors: Peraino JS, Schenk M, Zhang H, Li G, Hermanrud CE, Neville DM Jr, Sachs DH, Huang CA, Duran-Struuck R, Wang Z.
J Immunol Methods. 2013 May 31;391(1-2):103-11. doi: 10.1016/j.jim.2013.02.015. Epub 2013 Mar 5.
Expression and characterization of recombinant soluble porcine CD3 ectodomain molecules: mapping the epitope of an anti-porcine CD3 monoclonal antibody 898H2-6-15.
Authors: Peraino JS, Hermanrud CE, Springett L, Zhang H, Li G, Srinivasan S, Gusha A, Sachs DH, Huang CA, Wang Z.
Cell Immunol. 2012 Mar-Apr;276(1-2):162-7. doi: 10.1016/j.cellimm.2012.05.004. Epub 2012 May 18.